Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

GSK fuels TIGIT frenzy with $625M payout for iTeos’ mAb

iTeos’ Phase I anti-TIGIT mAb draws one of the largest-ever immuno-oncology deals 

By Lauren Martz, Senior Editor
June 14, 2021 11:00 AM UTC

GSK is betting big on one of the only next-generation checkpoint targets missing from its pipeline — and one of the only ones with strong clinical validation — through a major deal for a differentiated anti-TIGIT mAb from iTeos.

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) will pay $625 million up front for EOS-448 from iTeos Therapeutics Inc. (NASDAQ:ITOS), making it one of the largest single-asset immuno-oncology deals on record...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Genentech Inc.

Glaxosmithkline plc

Iteos Therapeutics Inc.

Roche